The UK and US have announced a significant trade agreement that will ensure no levies on UK drug products entering the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase funding on drugs through the National Health Service (NHS). This move guarantees that import taxes on these crucial products will be held at nothing for a period of the next three years.
This agreement follows recent warnings to significantly raise import taxes on branded pharmaceutical imports, with figures discussed as high as one hundred percent.
"This arrangement between the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces much-needed equity to American-British drug exports," a statement declared.
Economic Impact
Drugs are one of the UK's largest exports to the America, which is by far the biggest market for major companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period prior to September, the UK sold drugs valued at billions to the US. This amount accounted for 17.4% of all goods exports in that timeframe.
"This agreement safeguards jobs, increases capital expenditure and facilitates the UK to establish itself as a international leader for biotech and pharma," a government official remarked.
Key UK Commitments
The agreement involves several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a target to raise total NHS spending on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to stay within budget will be restricted at 15%. Previously, repayments exceeded 20%.
Industry Background
The pact takes place against a protracted row between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
These tensions were exacerbated by claims that US customers were charged a premium for the same drugs than people in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been paused or scrapped, while major funding commitments have been announced toward projects in the United States.
A senior figure acknowledged that the NHS had to spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the past decade.
